especially alcoholics with recalcitrant corneal ulcers2.
The problem that vitamin A deficiency poses to the West is only a tiny reflection of the 5 million new cases of xerophthalmia and the quarter million instances of associated corneal destruction and blindness suffered by Third World children each year3. Vernon et al. cite the high risk of subsequent ocular damage to their already deficient subjects. Indeed, sudden decompensation ofborderline vitamin A status can result in rapid corneal necrosis, even before conjunctival xerosis or Bitot's spots appear4. Measles is one of several potent precipitating factors, particularly in Africa5.
Recent data suggest that even mild, 'subclinical' deficiency may have important implications for growth, health and survival6. Mortality and infectious morbidity among Indonesian children are more closely correlated with vitamin A status than with general anthropometric measurements7'8. Periodic supplementation with large doses ofvitamin A twice a year9 or daily small-dose supplementation through fortification of a dietary staple'0 both appear to reduce preschool mortality by at least one-third".
Vitamin A treatment reduced case-fatality rates among Tanzanian children hospitalized with severe measles by 50%12. In Indonesia, supplementation increased linear'0 and ponderal'3 growth; while in Indonesia'0 and Latin America'4 it increased serum haemoglobin values. Small daily doses given to otherwise well nourished, healthy Australian children reduced the incidence of recurrent lower respiratory infection by a quarter'5.
The mechanism(s) by which vitamin A affects morbidity, mortality, growth and haematopoesis remain uncertain. Vitamin A is necessary for maintenance of mucous-secreting epithelial linings of a wide variety of organs. Deranged metaplasia no doubt interferes with their normal barrier function. Animal experiments in particular suggest roles for vitamin A in the regulation ofboth cell-mediated and humoral immunity'6. Whether the role of vitamin A on growth and haematopoesis is direct, or secondary to its effect on infection, is uncertain.
The significance of even marginal, 'subclinical' deficiency has important implications for the management of cystic fibrosis and related disorders. While one should be observant for signs and symptoms of frank deficiency, proper care will ensure these never occur in the first place; by the time they do, the individual may already have suffered potentially lethal consequences.
Daily supplementation with 5000-10 000 i.u. is often inadequate for maintaining normal vitamin A stores in patients with cystic fibrosis. The average daily intake of Americans lies within this range. Daily oral supplements of 25 000 to 50 000 i.u. vitamin A are often required. The optimal daily supplement needs to be titrated through periodic assessment. Serum retinol, as reliably determined by high performance liquid chromatography (HPLC), provides a useful index. As long as levels run well within the normal range (40-70 #g/dl [ 1.4-2.5 ismol/I]) the absence of even subclinical deficiency is reasonably assured. In some instances of severe lipid malabsorption, periodic intramuscular injections of watermiscible vitamin A may be necessary. Oil miscible vitamin A, as was used in Vernon's first case, is poorly absorbed from the injection site and should therefore be avoided.
Chronic, severe malabsorption of vitamin A, as sometimes encountered in cystic fibrosis, is one ofthe very few instances in which injectable vitamin A is required. The vast majority of vitamin A deficient children, including Third World children with severe malnutrition, diarrhoea and keratomalacia, respond as rapidly and successfully to oral as to injectable preparations'7. Oral Approximately 6000 patients aged less than'70 years die each year in England'aid Wales from"'colorectal cancer'. Hepatic metastages' are found at itopsy in 80% of cases of disseminated'to1orectal e cinoma, and in 20% these appear to'be limittoeth liver3'4.
It is probable that in some caaes Aistemifiation to other organs is by secondary metastasis from the liver5. It is clear that attempts to imnprove the outlook for patients with colorectal carciima must address the problem of hepatic metastases. In the UK, traditional mangement opatients with colorectal hepatic metastases emphasizes the maintenance of quality of life. It is usual for no treatment to be given prior to develo tif rmms and thereafter for any potentially ynmptoi-refie-Ving treatmtent, for example systemic 5FU, steroids or analgesics, to be given a trial. This approach is based on the view that since available treatments have virtually no effect on survival and hepatic m:etastases may be tic and slow growing6, it is preferable to avoid subjecting the patient to treatment-induced morbidity for no proven benefit. There is a danger that this view could become self-fulfilling if, as a result, few patients with hepatic metastases are entered into suitably designed trials evaluating the effect of treaments which are potentially beneficial to survival and quality of life.
Experience from a non-randomized pereonal series78 suggests that resection is'the most effective treatment for established hepatic metastasesachieving longterm (>5 year) survival for 20-25% ofpatients whose metastases are resected. Although only 10% of patients with colorpetal hepatic metastases are thought to be suitable for metastasis resection9, only a minority of the 600 patients who might be suitable each year in Englahd andt Wales actually undergo resection10. It is to be regretted that there are no randomized trials in the UK assessing the value of hepatic resection.
The majority of patients with colorectal liver metastases cannot be helped by resection. Results of systemic chemotherapy for disseminated colorectal carcinoma are disappointing, with partial response rates of roughly 20%111-3 and minal prolongation of survival in responders14. Studies administering FUDR (a 5FU analogue which has similar cytotoxic properties) via the hepatic artery15 indicate that a 10-fold increase in tumour FUPR-concentration can be achieved with reduced.systemic toxicity, compared to systemcE administration. In vitro and clinical studics'17 suggest that the cytotoxic effet of 5FU is, enhaniced by higher.tumour.conentratlon and time of exposure, so this approach maey,be more effective than systemic administration.This is ao sugested by experience of adjuvant 5FT3 liver perfusion via the portal vein at the timeof primary tumour resection. Survivil -?rmablyin patients with oocult hepatic metaatases -is improved over that of prospectively randoiized tontrol patients not receiving adjuvant 5FU liver perfUsion18. IniWti experience of continuous hepaticartery perfusion-for-established hepatic metastase suggested a partial response rate of greater than 50%19'-2Q8but the drawback was that the continuous hepatic perfSixon required for established inetastases involved an external catheter aid pump which-was unpleasant for the patient and prone to complication21.
The develbpment of a -totally implantable pump which is filled every 2 weeks via-needle puncture of the overlyiag skin has reduced pump and catheterrelated morbidity to less than 5%-, and allows the patient to undertake virtually all normal activities. Simnilar partial response rates.(30-88%) to those with the external system have been obtained23-2, but the absence in these studiesof a prospetiveljy randomized, symptomatically-palliated cQntrol group has meant. that the mere crucial questions!-does-the txeatment prolong-survival or sustain quality of lifecannot be answered.
Liver perfusion with FUDR is not without complicaionin particular, a significant but variable (8-56%) incidence13'6 of biliary sclerosis whichis -dose limiting. Nor does it-provide a cure--the majority of patients.eventually umb to extrahepatic, particularly pulmonary, metastases13. Despite this, the technique has been adopted in the United-States where over 8000 pumps.have been inserted-for oolorectal liver metastasee, many in patients not included in clinical trials. More recently the technique has been taken up.in western Europe.
T The uncritical adoption of such an unproven treatment is hardlysurprising since there is no remedy for established&colorectal liver metastases which is ofproven value and many patients will settle 0141-0768/89/ 010002-02/$02.00/0 01989 The Royal Society of Medicine
